News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
December, 2024
December 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
3031  
Apr 24, 2024, 09:58

KEYNOTE-A18 summarised by Sergio Cifuentes

Sergio Cifuentes, Cancer Research Project Manager at 

”KEYNOTE-A18.

  • Pembrolizumab + CRT in LACC
  •  mPFS NR in pembrolizumab group

24m PFS: 68% vs 57%

  • Pembrolizumab + CRT led to a 30% reduction in DR
  • OS at 24m: 87% vs 81%

Grade 3 or higher AE: 75% vs 69%.”

Read further.
Source: Sergio Cifuentes/X

cancer CENEIT México cervical cancer clinical trials CRT KEYNOTE-A18 trial OncoDaily Oncology pembrolizumab Sergio Cifuentes
Special Coverage
Drugs
Dec 21, 2024, 10:38
Hanna Foster: Market cap and Revenue of Cancer NGS Drugs providers in 2024
Insight
Dec 21, 2024, 10:35
30 Years of Leadership in Immuno-Oncology - Agenus
Blog
Dec 21, 2024, 10:19
A Portrait of Germline Pathogenic Variants in Breast Cancer Genes in Brazil
Dialogues
Dec 21, 2024, 10:09
Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market
Blog
Dec 21, 2024, 09:22
When the world of science and sports comes together! - The V Foundation
Blog
Dec 21, 2024, 09:16
Timely cancer treatment isn’t just a goal, It’s a necessity - European Cancer Organisation
Science
Dec 21, 2024, 09:06
Toni Choueiri: The Final Analysis of the JAVELIN Renal 101 trial
Blog
Dec 21, 2024, 09:00
Miriam Mutebi: Does Nipple and Areola Size Matter?
Science
Dec 21, 2024, 08:51
Wafik S. El-Deiry: Our recent review on Targeting the SMURF2-HIF1α axis
Science
Dec 21, 2024, 08:48
Oncology Brothers: Another ALK inhibitor gets FDA approval
Science
Dec 21, 2024, 08:42
Eric K. Singhi: Decoding clinical trial jargon
Science
Dec 21, 2024, 08:37
Gustavo Viani: The Role of Radiotherapy on the management of HCC